Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determining donanemab cessation thresholds?

The domain expert identified p-tau217 as the most clinically viable threshold marker, but its validation as a stopping rule requires prospective studies. This directly addresses the clinical practice gap identified in the source paper. Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab_20260416-135142 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab)